...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration
【24h】

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

机译：用于预测口腔剂型体内性能的体外模型：通过IMI奥贝罗合作的伙伴关系的最新进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled innovation, optimization and implementation of the requisite biorelevant in vitro tools. In this paper, we present an overview of the in vitro tools investigated during the collaboration and offer a perspective on their future use in enhancing the development of new oral drug products.
机译：在基于胃肠道（GI）生理学的关键方面的详细知识的体外工具的可用性以及它们对配方性能的影响以及随后的药物释放行为的影响是口服药物发育的成功和效率的基础。 在过去的六年里，改善的发展和优化，Biorelevant在体外工具中一直是IMI奥贝罗（口服生物发作措施工具）项目的基石。 通过汇集关键行业和学术伙伴，并通过将工具开发和优化与人类研究联系起来，以了解制定/ GI道路接口的行为，协作已经启用了必要的Biorelevant在体外工具的创新，优化和实施。 在本文中，我们概述了在合作期间调查的体外工具，并提供了对增强新口服药品的发展的未来使用的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号